SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-24-079078
Filing Date
2024-06-28
Accepted
2024-06-28 16:21:47
Documents
8
Effectiveness Date
2024-06-28

Document Format Files

Seq Description Document Type Size
1 S-8 june_2024_s-8_kalv.htm S-8 111336
2 EX-5.1 kalv-ex5_1.htm EX-5.1 16786
3 EX-23.1 kalv-ex23_1.htm EX-23.1 2788
4 EX-99.1 kalv-ex99_1.htm EX-99.1 811188
5 EX-FILING FEES kalv-exfiling_fees.htm EX-FILING FEES 19906
6 GRAPHIC img28983514_0.jpg GRAPHIC 32230
7 GRAPHIC img158624773_0.jpg GRAPHIC 3625
8 GRAPHIC img158624773_1.jpg GRAPHIC 3625
  Complete submission text file 0000950170-24-079078.txt   1018186
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: S-8 | Act: 33 | File No.: 333-280579 | Film No.: 241086050
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)